Test Price
2,800 AED✅ Home Collection Available
LHFPL5 Gene Deafness (Autosomal Recessive Type 67) NGS Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين LHFPL5 للصمم الوراثي المتنحي النوع 67 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited NGS processing and bioinformatics pipeline.
- Premium Logistics: Paid hospital‑grade home collection; ISO‑certified cold‑chain transport for DNA stability.
- Clinical Guidance: Telephonic post‑test clinical interpretation and mandatory pre‑test genetic counselling session (pedigree chart).
- Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731.
نضمن دقة تشخيصية تصل إلى 99.9% عبر مختبر معتمد دوليًا يطبق معايير ISO، مع الالتزام الكامل بالقانون الاتحادي رقم 41 لسنة 2024 المادة 87 وقانون حماية بيانات المرضى في الإمارات. خدمة استشارة وراثية قبل الفحص إلزامية لرسم شجرة العائلة.
Overview
The LHFPL5 gene test detects pathogenic variants causing autosomal recessive deafness type 67 (DFNB67), delivering actionable genetic diagnosis for early intervention and family planning. Utilising high‑coverage Next Generation Sequencing, it achieves sub‑single‑base resolution and a clinical confidence exceeding 99.9%.
يساعد هذا التحليل في تحديد الطفرات الجينية المسؤولة عن الصمم الوراثي المتنحي من النوع 67، مما يدعم التشخيص الدقيق وتخطيط الأسرة والإرشاد الوراثي.
| Parameter | DNA Labs UAE – LHFPL5 NGS Test | Closest Alternative (Standard Hearing Loss Panel) |
|---|---|---|
| Precision | 99.9% sensitivity with targeted deep sequencing ±100× coverage, validated by Sanger confirmation | Varied; may miss rare deep‑intronic variants |
| Methodology | NGS (Illumina NovaSeq) – full LHFPL5 coding region ±20 bp splice sites | Multiplex PCR or exome‑based panels |
| Turnaround Time | 3–4 weeks with prioritised reporting | 4–6 weeks |
| Price | 2800 AED | Varies; often higher for focused gene analysis |
| Genetic Counseling | Mandatory pre‑test pedigree session included | Not always provided |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY (DHA License: 61713011):
As a clinical molecular geneticist, I appreciate the emotional weight this test carries. The result provides families with a definitive molecular diagnosis, opening doors to targeted auditory rehabilitation and informed reproductive choices. I urge all patients to interpret the genetic report together with an audiologist and a clinical geneticist, never in isolation.
Medication Warning: Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria & ER Red Flags
- Exclusion: Sample contamination, insufficient DNA (<1 µg), lack of clinical history or signed consent.
- ER Red Flags: Sudden unilateral or bilateral hearing loss, acute vertigo, or focal neurological deficits require immediate ENT/neurology evaluation, not a genetic test.
- Minors: Valid parental consent and post‑test genetic counselling are mandatory per CDS Law 2026.
Patient FAQ & Clinical Guidance
1. How does LHFPL5 gene mutation lead to hearing loss?
LHFPL5 gene mutations impair inner ear hair cell stereocilia, causing autosomal recessive non‑syndromic hearing loss DFNB67. The encoded protein, tetraspan membrane protein of hair cell stereocilia, is essential for mechanoelectrical transduction; biallelic loss‑of‑function variants result in congenital, severe‑to‑profound bilateral sensorineural deafness that is stable over time.
تحدث طفرات جين LHFPL5 خللاً في أهداب خلايا الشعر السمعية، مما يسبب صممًا وراثيًا متنحيًا غير متلازمي من النوع DFNB67.
2. Who should consider this gene test?
Individuals with congenital bilateral sensorineural hearing loss and a family history of deafness should consider this. It is especially indicated when auditory neuropathy or syndromic features have been excluded and an autosomal recessive inheritance pattern is suspected.
يُنصح بإجراء الاختبار للأشخاص المصابين بصمم حسي عصبي ثنائي الجانب خلقي مع تاريخ عائلي للصمم.
3. How is the sample collected, and what is the turnaround time?
A blood sample, extracted DNA, or a single drop on an FTA card is collected at home; results take 3–4 weeks. Our mobile phlebotomist follows cold‑chain protocols, and the specimen is processed using NGS with rigorous quality metrics (Q30 ≥ 85%).
تُجمع العينة منزليًا عن طريق الدم أو الحمض النووي المستخلص أو قطرة دم على بطاقة FTA، وتظهر النتائج خلال 3–4 أسابيع.
Labs operation under Federal Decree‑Law No. 41 of 2024 (Art. 87), UAE PDPL, and CDS Law 2026. ISO 9001:2015 Certificate: INT/EGQ/2509DA/3139.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians